Ourania Tatsis - 17 Mar 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Reg. & Quality Off.
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
17 Mar 2022
Net transactions value
-$708,572
Form type
4
Filing time
21 Mar 2022, 16:15:55 UTC
Previous filing
28 Feb 2022
Next filing
10 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $700,030 -2,799 -5.6% $250.10 47,390 17 Mar 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale $8,542 -34 -0.07% $251.24 47,356 17 Mar 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $250.10 (range $250.00 to $250.55).
F3 Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.